A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 13 Nov 2018 Planned End Date changed from 15 Oct 2020 to 17 Feb 2021.
- 09 Jul 2018 Status changed from not yet recruiting to recruiting.
- 07 Jun 2018 Planned initiation date changed from 15 May 2018 to 18 Jun 2018.